Beta-blockers (All routes except ocular) (versus unexposed) updated on 12-17-2024

Intrauterine deaths (as a whole or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17127
R71767
Delteil - Beta-blockers, 2024 Intrauterine deaths (early, late and therapeutic) at least 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes Indications Antihypertensive: Only chronic indication (hypertension or cardiac) 2.07 [1.61;2.66] 62/823   10,077/161,052 10,139 823
ref
S14051
R55683
Xiang - Labetalol, 2020 Intrauterine fetal demise (NOS) during pregnancy (anytime or not specified) randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: Only chronic hypertension indication 0.59 [0.14;2.50] C 3/127   5/126 8 127
ref
Total 2 studies 1.36 [0.42;4.37] 10,147 950
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Delteil - Beta-blockers, 2024Delteil - Beta-blockers, 2024 2.07[1.61; 2.66]10,13982367%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Xiang - Labetalol, 2020Xiang - Labetalol, 2020 0.59[0.14; 2.50]812733%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 65% 1.36[0.42; 4.37]10,1479500.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.07[1.61; 2.66]10,139823 -NADelteil - Beta-blockers, 2024 1 case control studiescase control studies 0 RCTRCT 0.59[0.14; 2.50]8127 -NAXiang - Labetalol, 2020 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.07[1.61; 2.66]10,139823 -NADelteil - Beta-blockers, 2024 1 unexposed, sickunexposed, sick 0.59[0.14; 2.50]8127 -NAXiang - Labetalol, 2020 1 Tags Adjustment   - Randomisation  - Randomisation 0.59[0.14; 2.50]8127 -NAXiang - Labetalol, 2020 1   - Yes  - Yes 2.07[1.61; 2.66]10,139823 -NADelteil - Beta-blockers, 2024 1 Indications Antihypertensive   - Only chronic hypertension indication  - Only chronic hypertension indication 0.59[0.14; 2.50]8127 -NAXiang - Labetalol, 2020 1   - Only chronic indication (hypertensi ...  - Only chronic indication (hypertension or cardiac) 2.07[1.61; 2.66]10,139823 -NADelteil - Beta-blockers, 2024 1 All studiesAll studies 1.36[0.42; 4.37]10,14795065%NADelteil - Beta-blockers, 2024 Xiang - Labetalol, 2020 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.07[1.61; 2.66]10,139823 -NADelteil - Beta-blockers, 2024 1 unexposed, sick controlsunexposed, sick controls 0.59[0.14; 2.50]8127 -NAXiang - Labetalol, 2020 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (Intrauterine death) 1.52[0.79; 2.86]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT5 Abalos (Total reported fetal or neonatal deat ...Abalos (Total reported fetal or neonatal death (including miscarriage) (RCT versus no antihypertensive drugs/placebo)) 1.06[0.45; 2.53]0%-U,Sunexposed, sickAnyduring pregnancy (anytime or not specified)studies TTT11 metaPregmetaPreg 1.36[0.42; 4.37]65%950----Delteil - Beta-blockers, 2024 Xiang - Labetalol, 2020 20.510.01.0